Article Text

Download PDFPDF
A 14-Year-Old Female Patient With FIGO Stage IB Endometrial Carcinoma: A Case Report
  1. Takashi Mitamura, MD*,
  2. Hidemichi Watari, PhD*,
  3. Yukiharu Todo, PhD*,
  4. Takayuki Koshida, MD and
  5. Noriaki Sakuragi, PhD*
  1. *Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo; and
  2. Yakumo General Hospital, Yakumo, Japan.
  1. Address correspondence and reprint requests to Takashi Mitamura, Department of Obstetrics and Gynecology, Hokkaido University Graduate School of Medicine, Sapporo, Japan. E-mail: pikarun2620{at}jcom.home.ne.jp.

Abstract

Introduction: This is the second report on the conservative treatment of endometrial carcinoma in a female patient younger than fifteen years. Case A, a 14-year-old teenager, presented with menorrhagia. An endometrial biopsy revealed grade 2 endometrioid adenocarcinoma. The estrogen receptor and progesterone receptor were strongly positive in 60% and 90% of the tumor, respectively. Although she was administered medroxyprogesterone acetate for a month, it was not effective. She underwent standard surgery including a hysterectomy. She was thereafter free of disease 1 year after surgery. No estrogen receptor staining of the surgical specimen was observed, and 30% of the tumor was strongly positive for progesterone receptor. Direct DNA sequencing of exons 7 and 8 of PTEN and the K-ras codon 12 demonstrated the presence of no mutation. In addition, no dominant-negative p53 mutation was found by a yeast functional assay.

Conclusion: A uterine malignancy should therefore be included in the differential diagnosis in a young female patient complaining of abnormal genital bleeding.

  • Endometrial carcinoma
  • Teenager
  • Conservative treatment
  • Gene mutation

Statistics from Altmetric.com

Footnotes

  • Conflict of interest statement: The authors declare that they have no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.